This is a working overview of 肠促胰素, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
== Evolution == Genetic evidence from comparisons of multiple organisms showed that a glutathione-dependent formaldehyde dehydrogenase, identical to a class III alcohol dehydrogenase (ADH-3/ADH5), is presumed to be the ancestral enzyme for the entire ADH family. Early on in evolution, an effective method for eliminating both endogenous and exogenous formaldehyde was important and this capacity has conserved the ancestral ADH-3 through time. Gene duplication of ADH-3, followed by series of mutations, led to the evolution of other ADHs. The ability to produce ethanol from sugar (which is the basis of how alcoholic beverages are made) is believed to have initially evolved in yeast. Though this feature is not adaptive from an energy point of view, by making alcohol in such high concentrations so that they would be toxic to other organisms, yeast cells could effectively eliminate their competition. Since rotting fruit can contain more than 4% of ethanol, animals eating the fruit needed a system to metabolize exogenous ethanol. This was thought to explain the conservation of ethanol active ADH in species other than yeast, though ADH-3 is now known to also have a major role in nitric oxide signaling. In humans, sequencing of the ADH1B gene (responsible for production of an alcohol dehydrogenase polypeptide) shows several functional variants. In one, there is a SNP (single nucleotide polymorphism) that leads to either a Histidine or an Arginine residue at position 47 in the mature polypeptide.
Somalia's network of roads is 22,100 km (13,700 mi) long. As of 2000, 2,608 km (1,621 mi) streets are paved and 19,492 km (12,112 mi) are unpaved. A 750 km (470 mi) highway connects major cities in the northern part of the country, such as Bosaso, Galkayo and Garowe, with towns in the south. Sixty-two airports across Somalia accommodate aerial transportation; seven of these have paved runways. Among the latter, four airports have runways of over 3,047 metres (9,997 ft); two are between 2,438 and 3,047 m (7,999 and 9,997 ft) and one is 1,524 to 2,437 m (5,000 to 7,995 ft) long. There are fifty-five airports with unpaved landing areas. One has a runway of over 3,047 m; four are between 2,438 m and 3,047 m in length; twenty are 1,524 m to 2,437 m; twenty-four are 914 m to 1,523 m; and six are under 914 metres (2,999 ft). Major airports in the nation include the Aden Adde International Airport in Mogadishu, the Hargeisa International Airport in Hargeisa, the Kismayo Airport in Kismayo, the Baidoa Airport in Baidoa, and the Bender Qassim International Airport in Bosaso. Established in 1964, Somali Airlines was the flag carrier of Somalia. It suspended operations during the civil war. However, a reconstituted Somali government later began preparations in 2012 for an expected relaunch of the airline, with the first new Somali Airlines aircraft scheduled for delivery by the end of December 2013. According to the Somali Chamber of Commerce and Industry, the void created by the closure of Somali Airlines has since been filled by various Somali-owned private carriers.
Chicago, Illinois (includes Kenosha, Wisconsin) Clarksville, Tennessee Cincinnati, Ohio Columbia, Missouri Columbus, Ohio Dayton, Ohio Detroit, Michigan Indianapolis, Indiana Las Vegas, Nevada Lexington, Kentucky Louisville, Kentucky Minneapolis–St. Paul, Minnesota Nashville, Tennessee New York – New Jersey (includes Allentown, Pennsylvania) Orlando, Florida Phoenix, Arizona (no locations in Phoenix proper) St. Louis, Missouri Louisville and Columbus also house bulk-manufacturing (grocery-store sales, meat, and bun production) divisions. Company headquarters and the Porcelain Steel Buildings division are in Columbus, Ohio. In the late 20th century, White Castle tried expanding into three new cities, Philadelphia, Kansas City, and Cleveland-Akron. Those restaurants closed within several years. After a several decade hiatus, the company returned to the Kansas City area in 1985 only to leave again in 2001. White Castle entered the Cleveland-Akron area in 1987 and then exited in December 2014.
==== Metabolism ==== 2C-B appears to undergo substantial first-pass metabolism. It has been shown to be metabolized by liver hepatocytes, resulting in deamination and demethylation that produces several products. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites. Additionally, 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) can be produced by oxidative deamination. Further metabolism of BDMPE and BDMPAA may occur by demethylation. Alternatively, the later metabolites can be generated by demethylation of 2C-B followed by oxidative deamination. Deamination of 2C-B is mediated by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. There is species differentiation in the metabolism of 2C-B. Mice hepatocytes produce 4-bromo-2,5-dimethoxyphenol (BDMP), a previously unknown metabolite. Meanwhile, human, monkey, and rabbit hepatocytes produce 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), but dog, rat, and mouse hepatocytes do not. 2C-B's metabolites BDMPAA and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in humans occur at peak concentrations 280-fold and 17-fold higher than those of 2C-B with oral administration of 2C-B, respectively. Another known metabolite of 2C-B is 2-OH-2C-B (2-DM-2C-B; B-2-HMPEA). This compound is active and has similarly potency as a serotonin 5-HT2A receptor agonist as 2C-B itself in vitro.
Sources: en.wikipedia.org
==== Intracrine actions of PTHrP in cardiac cells ==== PTHrP exists in multiple isoforms, with some retained intracellularly rather than secreted. In cardiac myocytes and vascular smooth muscle cells, intracrine PTHrP is known to localize within the nucleus, where it regulates gene transcription, modulates cell proliferation, and affects intracellular calcium handling. One of the hallmark intracrine functions of PTHrP is its ability to influence angiogenesis. Studies have shown that nuclear PTHrP interacts with ribosomal DNA to upregulate genes involved in endothelial cell proliferation and vascular development. This action mirrors other intracrine factors, such as VEGF, which also regulate angiogenesis through nuclear localization.
=== Diet === People with autoimmune hyperthyroidism (such as in Graves' disease) should not eat foods high in iodine, such as edible seaweed and seafood. From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower rates of disease and goiters, and improved the lives of children whose mothers would not have eaten enough iodine during pregnancy, which would have lowered the IQs of their children.
=== 2010–2012: Early growth === Blockchain analysts estimate that Nakamoto had mined about one million bitcoins before he disappeared in 2010 and handed the network alert key and control of the code repository over to Gavin Andresen. Andresen later became lead developer at the Bitcoin Foundation, an organization founded in September 2012 to promote bitcoin. After early "proof-of-concept" transactions, the first major users of bitcoin were black markets, such as the dark web Silk Road. During its 30 months of existence, beginning in February 2011, Silk Road exclusively accepted bitcoins as payment, transacting ₿9.9 million, worth about $214 million.
David Christopher Hopkinson, lately Director of Housing, Great Grimsby Borough Council. For services to Housing and to Local Government. Christiana Valerie Horrocks, lately Grade 7, Department of Health. John Anthony Howley, , lately Deputy Assistant Commissioner, Metropolitan Police. For services to the Police. Brian Joseph Hunt, Senior Professional and Technology Superintending Grade, Ministry of Defence. Frank George Henry Hunt, Grade 7, Department of Trade and Industry. Edward Graham Hutchinson. For charitable services. Jane Iris Isbister, lately Chairman, Forth Valley Health Board. For services to Health Care. Professor Kenneth Henderson Jack, Emeritus Professor, University of Newcastle-upon-Tyne, and Honorary Professor, University of Wales, Swansea. For services to Science. David Richard Jenkins, Finance Director, Sony Manufacturing Company (UK). For services to Industry in Wales. Frederick Albert Jennings, Chairman, Midlands Regional Fisheries Advisory Committee. For services to Fisheries Policy. Terence Maxfield Jobling, lately Veterinary Officer, Ministry of Agriculture, Fisheries and Food. David Lawrence Johnston, Director General, National Inspection Council for Electrical Installation Contracting. For services to Electrical Safety. David Henry Marshall Jones, lately Grade 6, the Benefits Agency, Department of Social Security. Derek Jones, lately Head, Libraries and Art Services, Richmond upon Thames. For services to Librarianship. Linda Edwina Jones, Principal Scientific Officer, the Defence Evaluation and Research Agency, Ministry of Defence.
=== High potassium levels === Spironolactone can cause high blood potassium levels. Rarely, this can be fatal. Of people with heart disease prescribed typical dosages of spironolactone, 10 to 15% develop some degree of hyperkalemia, and 6% develop severe hyperkalemia. At a higher dosage, a rate of hyperkalemia of 24% has been observed. An abrupt and major increase in the rate of hospitalization due to hyperkalemia from 0.2 to 11% and in the rate of death due to hyperkalemia from 0.3 to 2.0 per 1,000 between early 1994 and late 2001 has been attributed to a parallel rise in the number of prescriptions written for spironolactone upon the publication of the Randomized Aldactone Evaluation Study (RALES) in July 1999. However, another population-based study in Scotland failed to replicate these findings. The risk of hyperkalemia with spironolactone is greatest in the elderly, in people with renal impairment (e.g., due to chronic kidney disease or diabetic nephropathy), in people taking certain other medications (including ACE inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, the antibiotic trimethoprim, and potassium supplements), and at higher dosages of spironolactone.
Sources: en.wikipedia.org
in the PAMn matrix which results in the best score is most likely to correspond to the mutations per amino acid separating the two proteins. Halving this value and dividing by the rate at which accepted mutations accumulate in the protein family provides an estimate of the time of divergence of these two proteins from their common ancestor. That is, the time of divergence in myr is
== Application == HIDs are sensitive to a broad range of components. They must use helium as a carrier gas. HID is classified as a mass sensitive detector, which means that its signal is proportional to the mass of analyte entering the detector per unit time. The analytes are destroyed during reaction, therefore, it is considered a destructive detector. The drawback to HIDs are that they contain a radioactive source. In the United States, this means they fall under a number of federal regulations concerning their use in the workplace, shipping, disposal, etc. Discharge ionization detectors have generally supplanted them.
of the absorbing species is known. However, it is possible to overcome this difficulty and measure the temperature simultaneously. There are number of ways to measure the temperature. A widely applied method, which can measure the temperature simultaneously, uses the fact that the line strength
It is especially common during the third trimester. It affects 1% of those under the age of 20 and 13% of those over the age of 44. Several ethnic groups including Asians, American Indians, Indigenous Australians, and Pacific Islanders are at higher risk. However, the variations in prevalence are also due to different screening strategies and diagnostic criteria. In 90% of cases, gestational diabetes resolves after the baby is born. Affected people, however, are at an increased risk of developing type 2 diabetes.
He played the opening six matches of the year, but struggled to make a significant impact, and he was dropped for the round seven match against Hawthorn at the Melbourne Cricket Ground. The same weekend, when Melksham was playing for Melbourne's VFL affiliate team, the Casey Demons, he was reported twice and subsequently received a one-match suspension. He was recalled to the senior side for the thirty-five-point win against Gold Coast at TIO Traeger Park in round ten. He played the remainder of the season in a new position as a defensive forward, and kicked twenty-one goals following his return, with Fox Sports Australia reporter, Brayden May, writing the new role had "breathed new life" into Melksham. Melksham excelled in his new role as a forward in 2018, finishing with a career-high 32 goals for the season as Melbourne made its first finals series since 2006. Highlights included a five-goal, best on ground performance, against Carlton in Round 9 and four goals against West Coast in a dramatic Round 22 win which confirmed Melbourne's position in the top 8. Despite Melbourne's drastic form slump in 2019, Melksham played consistently in the early rounds, before a foot injury in Round 8 against Gold Coast sidelined him for three months. He returned to form in 2020, playing every match of the shortened season, including captaining the side to victory against North Melbourne in Round 11, due to the absence of Max Gawn and Jack Viney.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。